NSAIDokkal

NSAIDokkal is a term used in pharmacology and clinical discussion to describe a framework for optimizing the safety and effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs). It is not a single drug but a concept that encompasses strategies, formulations, and guidelines intended to mitigate common NSAID-related adverse effects while preserving analgesic and anti-inflammatory benefits. The term appears in pharmacology discussions since the 2010s as a generic label for such strategies.

The concept covers several components. These include the co-prescription or co-formulation of NSAIDs with gastroprotective strategies (such as proton-pump inhibitors or misoprostol), development of NSAID formulations with modified or targeted release to reduce mucosal exposure, and, in some cases, pharmacogenomic-guided dosing to tailor therapy to individual risk profiles.

In practice, NSAIDokkal approaches aim to reduce gastrointestinal toxicity, renal impairment, and cardiovascular risk associated with NSAID use, particularly in older patients or those with prior ulcers, chronic kidney disease, or concomitant anticoagulant therapy. They emphasize risk assessment, patient education, and monitoring for adverse effects.

Regulation and evidence vary by component. Some NSAIDokkal strategies are part of standard clinical practice (e.g., co-prescription of PPIs for high-risk patients), while others are experimental or described in research settings. Clinicians weigh benefits and risks, considering age, comorbidities, concomitant medications, and duration of NSAID therapy.

See also: NSAIDs; gastroprotection; misoprostol; proton-pump inhibitors; pharmacogenomics.